JPRN-UMIN000005427CompletedPhase 2
Clinical trial of adjuvant chemotherapy with mFOLFOX6 (L-OHP+l-LV/5-FU)/XELOX(L-OHP+Capecitabine)after curative resection for stage III colon cancer - FACOS
Saitama Medical Center,Saitama Medical University0 sites130 target enrollmentStarted: April 12, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 130
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Synchronous multiple cancer and metachronous multiple cancer within 5-years. 2.Severe postoperative complications ,such as infection, ruptured suture, gastrointestinal bleeding. 3.Sensory peripheral neuropathy. 4.Uncontrolled hypertension. 5.Uncontrolled Diabetes Mellitus. 6.Marked abnormality of ECG, or clinically important cardiac disorders such as congestive heart failure, symptomatic coronary artery disease, uncontrolled arrythmia,history of cardiac infarction within 12 months. 7.Severe pulmonary complications, such as interstitial pneumonitis, pulmonary fibrosis, pulmonary emphysema. 8.With Evidence or history of psychiatric disability and central neurological disorder. 9.Diarrhea. 10.Systemic continuous administration of steroid drugs(p.o. or i.v.). 11.Pregnant, woman of child-bearing potential or lactating woman. 12.Not appropriate for the study at the physician's assessment.
Investigators
Similar Trials
Completed
Phase 2
Phase II trial of neoadjuvant chemotherapy with mFOLFOX6 plus Bevacizumab for resectable local recurrent rectal cancerResectable local recurrent rectal cancerJPRN-UMIN000002920agoya Surgical Oncology Group25
Completed
Phase 1
Feasibility study of adjuvant chemotherapy with FOLFOX(or XELOX) for 3 months followed by oral anticancer drug for 3 months in patients with completely resected colorectal cancerColorectal CancerJPRN-UMIN000004934PO Japan Southwest Oncology Research Support Organization(JSWOG)80
Completed
Phase 2
A phase II trial of adjuvant chemotherapy with 5-FU liver perfusion chemotherapy via the portal vein followed by gemcitabine plus S-1 (F-GS therapy) for patients with resectable pancreatic cancer (CCOG-1001)JPRN-UMIN000003768Chubu Clinical Oncology Group45
Completed
Phase 2
Phase II trial of adjuvant chemotherapy with modified medication of S-1 for pancreatic cancerpancreatic cancerJPRN-UMIN000002791Kyoto University Hospital35
Completed
Phase 2
Feasibility Study of Adjuvant Chemotherapy with UFT Following Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer (LOGIK-1001)Clinical Stage I Non-small Cell Lung Cancer Treated with Stereotactic Body Radiation TherapyJPRN-UMIN000004789ung Oncology Group in Kyushu, Japan (LOGIK)45